GSK completes study for COPD treatment
Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The 6,000-patient study, along with other recently completed studies, "supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012," the firm said.
Start your trial of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
